The 2021 Special Issue
Particle Therapy for Head and Neck Malignancies
- Closing date for submissions: August 31, 2020.
Special Issue Editor
Steven J. Frank, MD – The UT MD Anderson Particle Therapy Institute (USA)
Special Issue Associate Editors
- Paul M. Busse, MD, PhD - Massachusetts General Hospital (USA)
- Lei Dong, PhD - Hospital of the University of Pennsylvania (USA)
- Robert L. Foote, MD - Mayo Clinic – Rochester (USA)
- Piero Fossati, PhD – MedAustron (Austria)
- Hans Langendijk, MD, PhD - University Medical Centre Groningen (Netherlands)
- Nancy Y. Lee, MD, FASTRO - Memorial Sloan Kettering Cancer Center (USA)
- Jiade Lu, MD, MBA - Shanghai Proton/Heavy Ion Center (China)
- Hsiao-Ming Lu, PhD - Hefei Ion Medical Center (China)
- Jun-Etsu Mizoe, MD, PhD - Osaka Heavy Ion Therapy Center (Japan)
- Samir H. Patel, MD - Mayo Clinic – Phoenix (USA)
- Juliette Thariat, MD, PhD - Centre Baclesse / ARCHADE – Normandie Université (France)
The issue will feature research by international authors knowledgeable in head and neck cancer management with particle therapy. The articles within the special issue will cover the following topics:
- Biology: Enhancements of Proton Therapy in Head and Neck Tumors, RBE, LET
- Clinical:: Indications, Level of Evidence, Clinical Trials
- Physics: Treatment planning approaches, Monte Carlo robust optimization, Delivery, and quality assurance
- Health Policy: Value, Cost-effectiveness, NTCP Models, and Financial toxicity
The value of particle therapy in the management of head and neck tumors has rapidly evolved over the last decade, and head and neck cancer management currently represents one of the most common indications for the use of proton therapy. The primary goal of our head and neck special issue is to communicate the value of particle therapy for head and neck tumors. We will aim to expand our knowledge of clinical outcome measures in head and neck patients and provide long-term outcomes data and gather more data on the cost-effectiveness of particle therapy in head and neck tumors in response to the need for insurance authorization and increased patient access. We will provide greater clarity on treatment planning and quality assurance methodologies for emerging centers, thereby minimizing the risk of unnecessary side effects and complication, and communicate additional opportunities for personalization of particle therapy treatment through the biologic enhancement with concurrent approaches.
The IJPT is the official journal of the Particle Therapy Cooperative Group. IJPT is an electronic, open access peer‐reviewed journal that does not charge article‐processing fees. Articles are also digitally archived by PubMed Central, Portico, J-Gate, EBSCOhost, Google Scholar, the Directory of Open Access Journals (DOAJ), Elsevier's Scopus, and Web of Science, among others.
Submissions will be carefully selected through peer review to ensure quality, originality, appropriateness, significance, and readability.
For more information, email email@example.com.